An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma
Ravi Vij(Washington University in St. Louis), Susie Jun(Ellis Hospital), Kerry Taylor(Cancer Council Queensland), Noemi Horvath(South Australia Pathology), Yi Qian(Amgen (United States)), J. W. G. Smith(Amgen (United States)), Robert Vescio(Royal Adelaide Hospital), Andrew Spencer(The Alfred Hospital), Howard Yeh(Hospital de Santa Maria), Saroj Vadhan‐Raj(The University of Texas MD Anderson Cancer Center)
Cited by 97
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|New England Journal of Medicine|2016|783